Thrombotic diseases
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Any gender, age =18 years; (2) Using aspirin and ticagrelor for more than 3 days; (3) Chinese Han population; (4) The patients or their families agreed to voluntarily participated in this study, and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) patients with severe liver and renal insufficiency; (2) patients with severe digestive ulcer; (3) patients with malignant tumors; (4) patients with allergy or intolerance to aspirin or ticagrelor; (5) patients received anticoagulant antiplatelet or thrombolytic therapy in one months; (6) poor compliance, unable to cooperate with the treatment; (7) patients with severe abnormal platelet function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum aggregation rate of platelets, MAR;Related genotype; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of primitive platelets;Mean volume of primitive platelets;Average aggregation rate of platelets;The maximum platelet aggregation time; | — |
Countries
China
Contacts
Zhengzhou University People's Hospital, He'nan Provincial People's Hospital